CA-125: a potential prognostic indicator in patients with cervical cancer?
We evaluated 104 patients with newly diagnosed carcinoma of the cervix. Pre- and post-therapy and follow-up CA-125 levels were measured in 64 patients. Fifty-five patients (86%) had squamous cell carcinoma and 9 (14%) had adenocarcinoma of the cervix. At initial presentation 19 (30%) had CA-125 levels greater than 35 U/ml, 12 (19%) had levels of 16-35 U/ml, and 33 (51%) had levels less than 16 U/ml. Of the 11 patients who had pre- and post-treatment levels greater than 35 U/ml, 10 are dead of the disease and 1 is alive with persistent or recurrent disease. Of the 20 patients with elevated CA-125 levels at presentation who reverted to normal after therapy, 19 are clinically without evidence of disease at 14-46 months (median 27 months). Of the 33 patients with normal pre- and post-therapy CA-125 levels, 31 are clinically without evidence of disease. Two of these thirty-three patients had increasing CA-125 levels during routine follow-up and both have disease recurrence confirmed. There was no apparent correlation between CA-125 level and tumor type, tumor grade, or stage of disease. Our data suggest that patients with initially elevated CA-125 levels that revert to normal after therapy have a favorable prognosis. Persistent elevation of CA-125 levels during and after therapy in patients with carcinoma of the cervix was associated with a poor prognosis.
Goldberg
G L
GL
Department of Obstetrics and Gynecology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York 10461.
Sklar
A
A
O'Hanlan
K A
KA
Levine
P A
PA
Runowicz
C D
CD
D000230:Adenocarcinoma / Q000276:immunology*; D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000276:immunology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000276:immunology*
D015295:Antigens, Tumor-Associated, Carbohydrate